These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27344446)

  • 1. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
    Gascón F; Lozano J; Ponte B; de la Fuente D
    Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Research and development productivity map: visualization of industry status.
    Shimura H; Masuda S; Kimura H
    J Clin Pharm Ther; 2014 Apr; 39(2):175-80. PubMed ID: 24438433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of pharmaceuticals: ensuring the future of research and development.
    Serajuddin HK; Serajuddin AT
    J Am Pharm Assoc (2003); 2006; 46(4):511-6. PubMed ID: 16913396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microcap pharmaceutical firms: linking drug pipelines to market value.
    Beach R
    J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations.
    Proudman D; Desai U; Gomes DA; Khomenko M; Martin S; Nellesen D; Neumann U; Grabowski H
    J Med Econ; 2024; 27(1):1253-1266. PubMed ID: 39361016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing structure of the pharmaceutical industry.
    Cockburn IM
    Health Aff (Millwood); 2004; 23(1):10-22. PubMed ID: 15002624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On strategic choices faced by large pharmaceutical laboratories and their effect on innovation risk under fuzzy conditions.
    Puente J; Gascon F; Ponte B; de la Fuente D
    Artif Intell Med; 2019 Sep; 100():101703. PubMed ID: 31607342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial anatomy of neuroscience research.
    Dorsey ER; Vitticore P; De Roulet J; Thompson JP; Carrasco M; Johnston SC; Holloway RG; Moses H
    Ann Neurol; 2006 Dec; 60(6):652-9. PubMed ID: 17192926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspects of research and development contract terms in the bio/pharmaceutical sector.
    Banerjee T
    Adv Health Econ Health Serv Res; 2012; 23():1-33. PubMed ID: 23156659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus.
    Zoller FA; Boutellier R
    Drug Discov Today; 2013 Apr; 18(7-8):318-22. PubMed ID: 23318251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Financial aspects and the future of the pharmaceutical industry in the United States of america.
    Karamehic J; Ridic O; Ridic G; Jukic T; Coric J; Subasic D; Panjeta M; Saban A; Zunic L; Masic I
    Mater Sociomed; 2013 Dec; 25(4):286-90. PubMed ID: 24511277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from 60 years of pharmaceutical innovation.
    Munos B
    Nat Rev Drug Discov; 2009 Dec; 8(12):959-68. PubMed ID: 19949401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.
    Danzon PM; Nicholson S; Pereira NS
    J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.